Product category:
Assay kits
News Release from: MolecularMD
Edited by the Laboratorytalk Editorial
Team on 07 August 2007
MolecularMD to join CML Alliance
programme
MolecularMD is to participate as a preferred provider of Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) patient monitoring tests for CML Alliance
CML Alliance is a programme developed by Novartis Oncology to help improve outcomes for patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) There are an estimated 4600 new cases of CML diagnosed each year in the US and a total of 30,000 patients living with the disease
This article was originally published on Laboratorytalk on 5 Aug 2008 at 8.00am (UK)
Related stories
Infection control team winners applauded
Oxoid presented winners of the 2007/2008 Oxoid Infection Control Team of the Year Awards with their prizes at a celebratory dinner at the Walton Hall Hotel, Wellesbourne, Warwickshire, UK
Integrated DNA Technologies expands production
Integrated DNA Technologies (IDT), an oligonucleotide producer, has announced the completion of its newly-expanded European facility in the Haasrode Research Park area of Leuven, Belgium
The survival rates have dramatically increased since the FDA approval of imatinib mesylate (Gleevec Novartis), a tyrosine kinase inhibitor that targets the BCR-ABL protein.
Based on international clinical trials of imatinib (Gleevec), patients who achieve Major Molecular Response as measured by qRT-PCR have the best five year prognosis for progression free survival.
Sensitive molecular monitoring is a key component of patient treatment guidelines.
MolecularMD specialises in providing highly sensitive, standardised monitoring of the BCR-ABL oncogene expression by qRT-PCR and has exclusive collaborations with leading CML clinical research laboratories to help introduce international standardisation of the test.
"MolecularMD is happy to be a part of CML Alliance as a provider of standardised, quantitative BCR-ABL testing.
"Results provided by our lab will enable patients and their healthcare providers to confidently optimise treatment of CML", said Brian Druker, MolecularMD's scientific founder.
Dr Druker was the lead laboratory and clinical investigator of imatinb and is currently the director of the Oregon Health and Science University Cancer Institute.
Physicians who register with CML Alliance will have access to the various support and education components of the programme.
A web link within the CML Alliance website will direct physicians to the MolecularMD website where they can obtain documentation for sample submission and access support on interpretation of test results.
• MolecularMD: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
